Top-Rated StocksTop-Rated 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $14.34 -0.60 (-4.02%) (As of 10:04 AM ET) Add Compare Share Share Today's Range$14.05▼$14.8350-Day Range$9.76▼$14.9452-Week Range$9.44▼$26.49Volume34,147 shsAverage Volume406,116 shsMarket Capitalization$613.09 millionP/E RatioN/ADividend YieldN/APrice Target$30.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media 4D Molecular Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside112.7% Upside$30.50 Price TargetShort InterestBearish8.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.54) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector846th out of 942 stocksBiological Products, Except Diagnostic Industry147th out of 157 stocks 3.4 Analyst's Opinion Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.50, 4D Molecular Therapeutics has a forecasted upside of 112.7% from its current price of $14.34.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.82% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 7.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FDMT. Previous Next 2.7 News and Social Media Coverage News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 4D Molecular Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows5 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.54) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.Read More FDMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FDMT Stock News HeadlinesDecember 4, 2023 | finance.yahoo.com4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 ConferenceNovember 14, 2023 | finance.yahoo.comBroker Revenue Forecasts For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Are Surging HigherDecember 11, 2023 | Edge On The Street (Ad)U.S. Military Defense Fails Without Vanadium?The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply. November 12, 2023 | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportNovember 10, 2023 | markets.businessinsider.com4D Molecular Therapeutics Continues Growth: Q3 Financials and Progress in Ophthalmology Trials Reinforce Buy RatingNovember 10, 2023 | finanznachrichten.de4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.com4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsNovember 1, 2023 | finance.yahoo.com4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFCDecember 11, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 30, 2023 | finance.yahoo.com4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease CardiomyopathyOctober 26, 2023 | msn.comCantor starts 4D Molecular at overweight, says shares don't reflect progressOctober 25, 2023 | msn.comCantor Fitzgerald Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight RecommendationOctober 25, 2023 | finance.yahoo.com4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFCOctober 23, 2023 | finance.yahoo.com4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMDSeptember 25, 2023 | msn.com4D Molecular Therapeutics: Some Failures, A Few Key SuccessesSeptember 14, 2023 | finanznachrichten.de4D Molecular Therapeutics, Inc.: 4DMT Appoints Uneek Mehra as Chief Financial and Business OfficerSeptember 7, 2023 | finance.yahoo.com4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMDSeptember 7, 2023 | finance.yahoo.com4DMT to Participate in Upcoming Investor ConferencesAugust 9, 2023 | finance.yahoo.com4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 9, 2023 | finance.yahoo.comDespite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 yearJuly 31, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About 4D Molecular TherapeuticsJuly 31, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)July 29, 2023 | finance.yahoo.com4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023July 17, 2023 | finance.yahoo.com4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability DataJuly 14, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)July 10, 2023 | seekingalpha.com4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal PerformanceJune 9, 2023 | msn.comB of A Securities Maintains 4D Molecular Therapeutics (FDMT) Buy RecommendationSee More Headlines Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FDMT CUSIPN/A CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees144Year FoundedN/APrice Target and Rating Average Stock Price Target$30.50 High Stock Price Target$50.00 Low Stock Price Target$13.00 Potential Upside/Downside+104.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,490,000.00 Net Margins-436.30% Pretax Margin-436.30% Return on Equity-34.73% Return on Assets-31.45% Debt Debt-to-Equity RatioN/A Current Ratio18.07 Quick Ratio18.07 Sales & Book Value Annual Sales$21.99 million Price / Sales29.05 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book2.09Miscellaneous Outstanding Shares42,754,000Free Float38,179,000Market Cap$638.74 million OptionableNot Optionable Beta2.45 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. John F. Milligan Ph.D. (Age 62)Executive Chairman Comp: $150kDr. David H. Kirn M.D. (Age 61)Co-Founder, CEO & Director Comp: $920.97kDr. Fariborz Kamal Ph.D. (Age 60)President & COO Comp: $678.4kMs. Theresa Janke (Age 48)Co-Founder & Chief of Staff Comp: $652.32kMr. Uneek Mehra (Age 51)Chief Financial & Business Officer Mike ZanoniVP of Investor RelationsDr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal & Human Resources Officer and Corporate Secretary Dr. Robert Y. Kim M.B.A. (Age 62)M.D., Chief Medical Officer Dr. An Song Ph.D.Chief Development OfficerMs. Karen S. Carothers (Age 72)Controller More ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTESana BiotechnologyNASDAQ:SANAIntercept PharmaceuticalsNASDAQ:ICPTKura OncologyNASDAQ:KURAAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 3,458 shares on 12/6/2023Ownership: 0.128%Wellington Management Group LLPBought 3,638 shares on 12/1/2023Ownership: 0.404%Deutsche Bank AGSold 660,584 shares on 11/24/2023Ownership: 0.036%Morgan StanleySold 101,891 shares on 11/16/2023Ownership: 3.429%The Manufacturers Life Insurance Company Bought 2,232 shares on 11/15/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions FDMT Stock Analysis - Frequently Asked Questions Should I buy or sell 4D Molecular Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FDMT shares. View FDMT analyst ratings or view top-rated stocks. What is 4D Molecular Therapeutics' stock price target for 2024? 8 brokers have issued 1 year price objectives for 4D Molecular Therapeutics' shares. Their FDMT share price targets range from $13.00 to $50.00. On average, they expect the company's share price to reach $30.50 in the next twelve months. This suggests a possible upside of 112.7% from the stock's current price. View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts. How have FDMT shares performed in 2023? 4D Molecular Therapeutics' stock was trading at $22.21 at the beginning of the year. Since then, FDMT stock has decreased by 35.4% and is now trading at $14.34. View the best growth stocks for 2023 here. Are investors shorting 4D Molecular Therapeutics? 4D Molecular Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,770,000 shares, an increase of 7.4% from the October 31st total of 3,510,000 shares. Based on an average trading volume of 337,800 shares, the days-to-cover ratio is presently 11.2 days. View 4D Molecular Therapeutics' Short Interest. When is 4D Molecular Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our FDMT earnings forecast. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.43. The firm had revenue of $20.20 million for the quarter, compared to analyst estimates of $6.41 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.73%. What ETFs hold 4D Molecular Therapeutics' stock? ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did 4D Molecular Therapeutics IPO? (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? 4D Molecular Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.74%), Morgan Stanley (3.43%), Northern Trust Corp (0.86%), Healthcare of Ontario Pension Plan Trust Fund (0.83%), Charles Schwab Investment Management Inc. (0.61%) and Wellington Management Group LLP (0.40%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko and Scott Bizily. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:FDMT) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.